sequenom inc (SQNM) Key Developments
Nicox Inc. and Sequenom Announce the Launch of Expanded Access to ReRetnaGene(TM) Test Portfolio in the U.S
Jun 19 14
Nicox S.A. and Sequenom Inc. announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(TM) portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual's risk for advanced age-related macular degeneration (AMD). AMD is the most common cause of visual impairment and the leading cause of blindness in the elderly population in the developed world. The RetnaGene portfolio includes two laboratory-developed genetic tests performed exclusively by Sequenom Laboratories that evaluate an individual's risk of advanced AMD. The RetnaGene AMD test assesses the risk for wet AMD (also called choroidal neovascularization, CNV) within two, five and ten years in patients aged 55 and older with early or intermediate dry AMD. The RetnaGene(TM) LR test assesses the lifetime risk of advanced AMD (wet or dry) in patients who have not been diagnosed with AMD, aged 55 and older and/or with a family history of AMD. The RetnaGene tests evaluate genotype and other known risk factors, giving a more complete assessment of a patient's individual risk for developing advanced AMD than with current phenotype-based standards.
Sequenom Inc. Receives FDA Clearance for IMPACT Dx System
Jun 16 14
Sequenom Inc. announced that it has received premarket 510(k) clearance from the United States Food and Drug Administration (FDA) to market its IMPACT Dx Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx System. The IMPACT Dx Factor V Leiden and Factor II Genotyping Test is performed on the IMPACT Dx System, and is indicated for use as an aid in the diagnosis of patients with suspected thrombophilia. As previously indicated, Sequenom completed the sale of its Bioscience business segment to Agena Bioscience. As part of this sale, the Premarket 510(k) Notification will transfer to Agena Bioscience and Sequenom will receive $2 million upon the achievement of this regulatory milestone.
Sequenom Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:00 PM
May 21 14
Sequenom Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Carolyn D. Beaver, Chief Accounting Officer and Vice President, William J. Welch, President and Chief Operating Officer.
Sequenom Inc. Announces Retirement of Allan T. Bombard as Chief Medical Officer
May 2 14
On April 28, 2014, Sequenom Inc. announced that Allan T. Bombard, Chief Medical Officer of the company, informed the company that he will retire from employment with the company as of the company's next annual meeting of stockholders on June 10, 2014.
Sequenom Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014
May 1 14
Sequenom reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. The company reported record revenue of $46.3 million for the first quarter of 2014, an increase of 20% compared to revenue of $38.5 million for the first quarter of 2013. Net loss for the first quarter of 2014 was $15.7 million or $0.13 per share, as compared to net loss of $29.4 million or $0.26 per share, for the same period in 2013. Adjusted net loss for the first quarter of 2014 was $14.7 million or $0.13 per share. Net cash used in operating activities was $13.2 million for the first quarter of 2014, compared to $19.7 million in the same period in the prior year. Loss from operations was $13.5 million against $27 million of prior year period. Loss before income taxes was $15.5 million against $29.3 million of prior year period.